MX2020004271A - Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. - Google Patents

Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.

Info

Publication number
MX2020004271A
MX2020004271A MX2020004271A MX2020004271A MX2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A
Authority
MX
Mexico
Prior art keywords
dpp3
epitopes
prevention
binding
treatment
Prior art date
Application number
MX2020004271A
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
4TEEN4 Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4TEEN4 Pharmaceuticals GmbH filed Critical 4TEEN4 Pharmaceuticals GmbH
Publication of MX2020004271A publication Critical patent/MX2020004271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención provee un aglutinante dirigido a y que se une a una proteína DPP3 o derivados funcionales de la misma y su uso en un método de prevención o tratamiento de enfermedades o condiciones agudas en un paciente, en la cual dicha enfermedad o condición aguda está asociada con estrés oxidativo. Con este contexto, específicamente la presente invención provee un aglutinante que está dirigido a y que se une a un epítope de conformidad con SEQ ID NO.: 2, en el cual dicho epítope está comprendido en una proteína DPP3 o un derivado funcional de la misma, y en el cual dicho aglutinante de DPP3 reconoce a y se une a por lo menos tres aminoácidos de SEQ ID NO.: 2.
MX2020004271A 2017-10-25 2018-10-24 Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. MX2020004271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198420 2017-10-25
PCT/EP2018/079197 WO2019081595A2 (en) 2017-10-25 2018-10-24 DPP3 BINDER DIRECTED TO AND BINDING SPECIFIC DPP3 EPITOPES AND USE THEREOF IN THE PREVENTION OR TREATMENT OF OXIDATIVE STRESS ASSOCIATED DISEASES / CONDITIONS

Publications (1)

Publication Number Publication Date
MX2020004271A true MX2020004271A (es) 2020-07-29

Family

ID=60186108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004271A MX2020004271A (es) 2017-10-25 2018-10-24 Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.

Country Status (13)

Country Link
US (2) US11530276B2 (es)
EP (2) EP4527458A3 (es)
JP (2) JP7424972B2 (es)
KR (2) KR102835427B1 (es)
CN (2) CN111542548B (es)
AU (2) AU2018356441C1 (es)
BR (1) BR112020006563A2 (es)
CA (1) CA3080251A1 (es)
IL (1) IL274009B2 (es)
MX (1) MX2020004271A (es)
MY (1) MY202502A (es)
SG (1) SG11202002594PA (es)
WO (1) WO2019081595A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102835427B1 (ko) * 2017-10-25 2025-07-21 4틴4 파마슈티컬스 게엠베하 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도
CN113557031A (zh) * 2018-12-21 2021-10-26 4Teen4制药有限公司 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
JP2022546061A (ja) * 2019-08-30 2022-11-02 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング ショック症治療のための治療法の誘導および／または治療法の監視
US20230193348A1 (en) * 2020-02-27 2023-06-22 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
BR112022017277A2 (pt) * 2020-03-16 2022-10-18 4TEEN4 Pharmaceuticals GmbH Dpp3 em pacientes infectados com coronavírus
JP2025541138A (ja) 2022-12-15 2025-12-18 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤な患者における肺機能の改善のためのｄｐｐ３阻害剤
CN115804836A (zh) * 2022-12-27 2023-03-17 中国人民解放军海军特色医学中心 一种中枢小分子蛋白dpp3在制备降压药物中的应用
EP4687942A1 (en) 2023-03-29 2026-02-11 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
WO2026046947A1 (en) 2024-08-26 2026-03-05 4TEEN4 Pharmaceuticals GmbH Anti-dpp3 antibody directed to and binding to dpp3 for the treatment of shock in extreme-critically ill patients

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001016334A2 (en) 1999-09-01 2001-03-08 Incyte Genomics, Inc. Human hydrolytic enzymes
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2005106486A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
JP2006230318A (ja) 2005-02-25 2006-09-07 Maruishi Pharmaceutical Co Ltd 関節リウマチの診断方法
WO2007117444A2 (en) 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
WO2010093872A2 (en) 2009-02-13 2010-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular-based method of cancer diagnosis and prognosis
DK2414542T3 (da) * 2009-03-30 2017-11-27 Tel Hashomer Medical Res Infrastructure & Services Ltd Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
RU2553333C2 (ru) 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
MX2015009403A (es) 2013-01-28 2017-07-04 Nuevas Alternativas Naturales Thermafat S A P I De C V Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox.
CN104946646B (zh) * 2014-03-25 2020-03-31 中国医学科学院基础医学研究所 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用
DE112017002105T5 (de) 2016-04-21 2019-04-25 Sphingotec Therapeutics Gmbh Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren
KR102835427B1 (ko) * 2017-10-25 2025-07-21 4틴4 파마슈티컬스 게엠베하 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도

Also Published As

Publication number Publication date
KR20200083509A (ko) 2020-07-08
EP4527458A3 (en) 2025-07-09
EP3700937A2 (en) 2020-09-02
CN118791621A (zh) 2024-10-18
BR112020006563A2 (pt) 2020-10-13
US11530276B2 (en) 2022-12-20
KR20250111243A (ko) 2025-07-22
AU2018356441B2 (en) 2024-12-19
AU2018356441A9 (en) 2024-12-19
IL274009A (en) 2020-05-31
EP4527458A2 (en) 2025-03-26
JP2024041975A (ja) 2024-03-27
CN111542548A (zh) 2020-08-14
CN111542548B (zh) 2024-07-30
US20210206876A1 (en) 2021-07-08
AU2018356441C1 (en) 2026-03-05
RU2020116450A (ru) 2021-11-25
AU2018356441A1 (en) 2020-04-16
MY202502A (en) 2024-05-01
JP7424972B2 (ja) 2024-01-30
JP2021500376A (ja) 2021-01-07
AU2025201656A1 (en) 2025-03-27
RU2020116450A3 (es) 2021-12-21
WO2019081595A2 (en) 2019-05-02
KR102835427B1 (ko) 2025-07-21
IL274009B1 (en) 2024-09-01
US20230295344A1 (en) 2023-09-21
WO2019081595A4 (en) 2019-09-06
WO2019081595A3 (en) 2019-06-20
SG11202002594PA (en) 2020-04-29
CA3080251A1 (en) 2019-05-02
IL274009B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
MX2020004271A (es) Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12017502180A1 (en) Tau-binding antibodies
EP3807321A4 (en) ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF
IL272524A (en) Clec9a binding agents and use thereof
BR112016022841A2 (pt) cadeia j modificada
BR112016030670A2 (pt) "imunocitoquina"
MX384379B (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-fármaco.
PE20200617A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
MX2022005211A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
TN2017000539A1 (en) Tau-binding antibodies
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
MX2017014136A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
EP3601569A4 (en) PCSK9 EXPRESSION MODULATORS
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MX420249B (es) Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos.
CO2017003067A2 (es) Compuestos de dipeptidil-cetoamida
CL2020003364A1 (es) Tratamiento antidiabético cardiovascular y renal seguro
MX374569B (es) Compuestos organolépticos novedosos.
BR112018067693A2 (pt) compostos de selenogalactosídeo para a prevenção e tratamento de doenças associadas com galectina e usos dos mesmos